All In Biotech

Drug Trial Radar · NCT07122414

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 16, 2024

Primary completion

Oct 10, 2027

Study completion Oct 10, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG. To evaluate the preliminary efficacy of FL115 alone or in combination with BCG in the treatment of NMIBC. The study consists of three parts: FL115 monotherapy dose escalation (Phase Ia), FL115 combined with BCG dose escalation (Phase Ib), and FL115 combined with BCG cohort expansion (Phase II). Each subject will receive FL115 alone or in combination with intravesical BCG, administered over three treatment periods: induction, enhanced induction/maintenance 1, and maintenance 2.

Conditions

  • Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

  • FL115Drug

    FL115 single agent dose escalation,

  • FL115+BCGDrug

    FL115 in combination with BCG

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: up to 15 months
  2. RP2DTime frame: up to 15 months
  3. Safety and tolerabilityTime frame: through study completion, up to 5 years
  4. Complete ResponseTime frame: 36 months
  5. Disease-Free RateTime frame: 12 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Fujian, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.